OnKure Therapeutics, Inc.

OnKure Therapeutics, Inc. is a U.S.-based clinical-stage biopharmaceutical company focused on discovering and developing precision medicines for cancers and other diseases. Its pipeline centers on small-molecule drug candidates designed with structure-based drug design to selectively target mutated forms of biologically validated proteins, including PI3Kα.

10.28

10.28

— OnKure Therapeutics, Inc.
%
Clinical-stage drug candidates100% Investigational small-molecule therapies being advanced through preclinical and clinical development.
PI3Kα-targeted programs0% Programs designed to selectively inhibit mutated PI3Kα drivers in cancer and related diseases.
Drug discovery platform0% Structure-based discovery capabilities using medicinal chemistry, x-ray crystallography, and computation.

OnKure does not sell commercial products today; its near-term counterparties are research sites, CROs, manufacturers,...

  • Clinical research organizations and trial sitesprimary

    They support the development of OKI-219 and future programs by running studies and generating clinical data.

  • Regulatory authoritiesprimary

    They review clinical, manufacturing, and safety data needed for marketing approval.

  • Manufacturing and supply partnersprimary

    They provide drug substance, finished product, packaging, and scale-up support for development and launch.

  • Potential future patients and physiciansemerging

    They would use approved therapies for cancers and other diseases driven by specific mutations.

  • Third-party payorsemerging

    They determine coverage and reimbursement that would affect adoption of any approved product.

OnKure is incorporated in Delaware and has its principal executive offices in Boulder, Colorado...

  • •Headquartered in Boulder, Colorado
  • •Incorporated in Delaware
  • •Clinical and regulatory activity is centered in the United States
  • •Future patent protection and commercialization may extend internationally
  • •Facilities are leased rather than owned

OnKure’s strategy is to advance a focused pipeline of precision medicines built around mutated PI3Kα and related...

01
Advance OKI-219 through clinical developmentshort-term

The company is substantially dependent on this lead program for value creation.

02
Develop additional product candidatesmedium-term

A broader pipeline reduces single-asset dependence and expands long-term optionality.

03
Establish manufacturing and commercialization readinessmedium-term

Biopharma value depends on scalable supply, launch capability, and market access if approved.

OnKure faces the typical risks of a clinical-stage biotech: no approved products, no product revenue, and heavy...

high

Lead-asset concentration

The company is substantially dependent on OKI-219, so setbacks would materially harm the business.

Scope
OKI-219
Materiality
high
high

Clinical development failure

Drug candidates can fail to demonstrate efficacy, safety, or tolerability in trials.

Scope
Clinical-stage pipeline
Materiality
high
high

Regulatory approval risk

Approval depends on successful trial results, manufacturing readiness, and agency review.

Scope
FDA and other regulators
Materiality
high
high

Financing risk

The company expects to need additional capital to fund operations and development.

Scope
Equity, debt, collaborations
Materiality
high
medium

Commercialization and reimbursement risk

Even approved therapies may face coverage, pricing, and adoption barriers.

Scope
Payors, physicians, patients
Materiality
medium
Research and development expense
Major driver of operating loss
Lease accounting
Occupancy and balance sheet presentation
Fair value of financing instruments
Financing gains/losses and dilution analysis
Stock-based compensation
Operating expense and dilution

NextCure, Inc.

NXTC · Pharmaceutical Preparations

Prelude Therapeutics Inc

PRLD · Pharmaceutical Preparations

TuHURA Biosciences, Inc./NV

HURA · Pharmaceutical Preparations

Enliven Therapeutics, Inc.

ELVN · Pharmaceutical Preparations

Oric Pharmaceuticals, Inc.

ORIC · Pharmaceutical Preparations

NovoCure Ltd

NVCR · Surgical & Medical Instruments & Apparatus

: 29/04/2026